Patricia A. Seymour

Pfizer (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index2.2kcitations36works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(9), Neuroscience and Neuropharmacology Research(8), Tryptophan and brain disorders(7), Neurotransmitter Receptor Influence on Behavior(4), Neuropeptides and Animal Physiology(4)

Publications36 total

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate
Journal of Medicinal Chemistry·2018· 27 citedOpen Access
The Discovery and Characterization of the α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Potentiator <i>N</i> -{(3 <i>S</i> ,4 <i>S</i> )-4-[4-(5-Cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242)
Journal of Medicinal Chemistry·2015· 29 cited
CCDC 1402068: Experimental Crystal Structure Determination
The Cambridge Structural Database·2015Open Access
Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating
Psychopharmacology·2013· 27 citedOpen Access
Pharmacological disruption of mouse social approach behavior: Relevance to negative symptoms of schizophrenia
Behavioural Brain Research·2013· 36 cited
Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo
Journal of Pharmacology and Experimental Therapeutics·2012· 79 cited
Modulation of NMDA receptor function by inhibition of d-amino acid oxidase in rodent brain
Neuropharmacology·2011· 40 cited
P4‐197: A selective ORL1 antagonist enhances hippocampal function and reverses pharmacologically induced cognitive deficits in rodents
Alzheimer s & Dementia·2011
α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties
Behavioural Pharmacology·2011· 48 citedOpen Access
P3‐380: Dendritic spine density deficits in the hippocampal CA1 region of young Tg2576 mice are ameliorated with the PDE9A inhibitor PF‐04447943
Alzheimer s & Dementia·2010· 15 citedOpen Access
Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists
Psychopharmacology·2010· 56 cited
Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction
Behavioural Brain Research·2010· 42 cited
Glycine transporter inhibition reverses ketamine-induced working memory deficits
Neuroreport·2010· 50 cited
Preclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects on reward, mood and cognition
Biochemical Pharmacology·2009· 115 cited
Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect
European Journal of Pharmacology·2009· 85 citedOpen Access
Towards a Biological Understanding of ADHD and the Discovery of Novel Therapeutic Approaches
Elsevier eBooks·2008· 2 cited
List of Contributors
Elsevier eBooks·2008
CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity
Neuropharmacology·2006· 131 cited
The Pharmacology of CP‐154,526, a Non‐Peptide Antagonist of the CRH1 Receptor: A Review
CNS Drug Reviews·2003· 112 citedOpen Access
CP-465,022, a Selective Noncompetitive AMPA Receptor Antagonist, Blocks AMPA Receptors but Is Not Neuroprotective In Vivo
Stroke·2003· 30 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Christopher J. Schmidt(8), Mihály Hajós(7), Anne W. Schmidt(7), Victor Guanowsky(6), Mark J. Majchrzak(6), Dina McGinnis(5), William E. Hoffmann(4), Stafford McLean(4), Christopher L. Shaffer(4), Cheng Chang(4), Lorraine A. Lebel(3), B. Kenneth Koe(3), Hans Rollema(3), David W. Schulz(3), Jean Morrone(3), Robin J. Kleiman(3), Frank S. Menniti(3), Patrick R. Verhoest(3), Alan H. Ganong(3), Dianne K. Bryce(3)